- Home
- LMND vs SLNO Comparison
LMND vs SLNO Comparison
Compare LMND & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMND
- SLNO
- Stock Information
- Founded
- LMND 2015
- SLNO 1999
- Country
- LMND United States
- SLNO United States
- Employees
- LMND N/A
- SLNO N/A
- Industry
- LMND Property-Casualty Insurers
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- LMND Finance
- SLNO Health Care
- Exchange
- LMND Nasdaq
- SLNO Nasdaq
- Market Cap
- LMND 2.0B
- SLNO 2.3B
- IPO Year
- LMND 2020
- SLNO 2014
- Fundamental
- Price
- LMND $26.78
- SLNO $69.98
- Analyst Decision
- LMND Hold
- SLNO Strong Buy
- Analyst Count
- LMND 9
- SLNO 8
- Target Price
- LMND $34.44
- SLNO $95.75
- AVG Volume (30 Days)
- LMND 1.8M
- SLNO 2.6M
- Earning Date
- LMND 04-29-2025
- SLNO 05-08-2025
- Dividend Yield
- LMND N/A
- SLNO N/A
- EPS Growth
- LMND N/A
- SLNO N/A
- EPS
- LMND N/A
- SLNO N/A
- Revenue
- LMND $526,500,000.00
- SLNO N/A
- Revenue This Year
- LMND $27.59
- SLNO N/A
- Revenue Next Year
- LMND $32.79
- SLNO N/A
- P/E Ratio
- LMND N/A
- SLNO N/A
- Revenue Growth
- LMND 22.50
- SLNO N/A
- 52 Week Low
- LMND $14.03
- SLNO $36.61
- 52 Week High
- LMND $53.85
- SLNO $74.00
- Technical
- Relative Strength Index (RSI)
- LMND 39.48
- SLNO 62.10
- Support Level
- LMND $26.08
- SLNO $57.01
- Resistance Level
- LMND $28.20
- SLNO $71.00
- Average True Range (ATR)
- LMND 2.58
- SLNO 5.29
- MACD
- LMND -0.23
- SLNO -0.08
- Stochastic Oscillator
- LMND 29.21
- SLNO 76.34
About LMND Lemonade Inc.
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. Geographically, it operates in California, Texas, New York, New Jersey, Illinois, Georgia, Washington, Colorado, Pennsylvania, Oregon and others.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.